Form 8-K - Current report:
SEC Accession No. 0001558370-25-002702
Filing Date
2025-03-11
Accepted
2025-03-11 16:00:18
Documents
15
Period of Report
2025-03-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vygr-20250311x8k.htm   iXBRL 8-K 40937
2 EX-99.1 vygr-20250311xex99d1.htm EX-99.1 158760
3 GRAPHIC vygr-20250311xex99d1001.jpg GRAPHIC 7635
  Complete submission text file 0001558370-25-002702.txt   342705

Data Files

Seq Description Document Type Size
4 EX-101.SCH vygr-20250311.xsd EX-101.SCH 3300
5 EX-101.LAB vygr-20250311_lab.xml EX-101.LAB 15266
6 EX-101.PRE vygr-20250311_pre.xml EX-101.PRE 9841
17 EXTRACTED XBRL INSTANCE DOCUMENT vygr-20250311x8k_htm.xml XML 4663
Mailing Address 75 HAYDEN AVENUE LEXINGTON MA 02421
Business Address 75 HAYDEN AVENUE LEXINGTON MA 02421 857-259-5340
Voyager Therapeutics, Inc. (Filer) CIK: 0001640266 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37625 | Film No.: 25727473
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)